Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc director Mohsen Sohi reported several equity transactions. On 2026-08-12, he exercised 4,058 options with a $86.23 exercise price into ordinary shares and sold 4,058 shares at a weighted average price of $235.78 per share, with individual sale prices ranging from $235.73 to $235.89. On 2026-08-10, he received a grant of 1,099 fully vested nonqualified stock options with a $238.91 exercise price and 1,229 fully vested Career Restricted Stock Units, each RSU representing one ordinary share to be delivered six months after his Board service ends.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
STERIS plc director Louis Shapiro received a grant of 1,025 Career Restricted Stock Units, each representing one ordinary share. These units are fully vested immediately and will be settled in ordinary shares six months after the cessation of his Board service, bringing his reported derivative holdings to 2,000 units.
STERIS plc director Nirav R. Shah reported equity awards consisting of stock options and restricted stock units. On 2026-08-10, he received 1,506 nonqualified stock options to purchase STERIS ordinary shares at an exercise price of $238.91 per share; these options are fully vested and exercisable immediately, and expire on 2036-08-10. On the same date, he also received 512 Career Restricted Stock Units, each representing one ordinary share to be delivered six months after his Board service ends; these RSUs are fully vested immediately. Following the RSU grant, his directly held equity related to these units totals 7,015 shares.
Martin Paul Edward reported acquisition or exercise transactions in this Form 4 filing.
STERIS plc director Martin Paul Edward reported compensation-related equity grants. He received 1,506 nonqualified stock options exercisable immediately at $238.91 per share, expiring August 10, 2036, and 512 Career Restricted Stock Units, which are fully vested and will be settled in ordinary shares six months after his Board service ends, bringing his directly held Career RSUs to 5,074.
HOLLAND CHRISTOPHER S reported acquisition or exercise transactions in this Form 4 filing.
STERIS plc director Christopher S. Holland received a grant of 1,025 Career Restricted Stock Units, each representing the right to receive one ordinary share. The units are fully vested immediately and will be settled in ordinary shares six months after his Board service ends. Following this award, he directly holds 5,989 Career Restricted Stock Units.
STERIS plc director Cynthia L. Feldmann received equity awards on 2026-08-10. She was granted 1,506 nonqualified stock options to buy ordinary shares at an exercise price of $238.91 per share, fully vested and exercisable immediately, expiring on 2036-08-10. She also received 512 fully vested Career Restricted Stock Units, each representing one ordinary share to be settled six months after her Board service ends, bringing her directly held Career RSUs to 8,640 units.
Boulud Pierre reported acquisition or exercise transactions in this Form 4 filing.
STERIS plc reported that director Pierre Boulud received a grant of 1,025 Career Restricted Stock Units, each representing the right to receive one STERIS ordinary share. The units are fully vested immediately and will be settled in ordinary shares six months after the cessation of the Director's Board service, bringing his reported direct holdings in these units to 1,392.
STERIS plc director Esther M. Alegria received new equity-based compensation. On 2026-08-10 she was granted 1,506 nonqualified stock options with an exercise price of $238.91 per share, expiring on 2036-08-10; these options are fully vested and exercisable immediately. She was also granted 512 Career Restricted Stock Units, each representing one ordinary share, which are fully vested and will be settled in shares six months after her Board service ends. Following these awards, her directly held derivative interests reported in this filing total 3,408 Career RSUs and 1,506 stock options.
STERIS plc reported stronger fiscal 2027 first‑quarter results, with revenue up 7.3% to $1,492.7 million, driven by higher volume in Healthcare and Life Sciences and pricing across all segments. Product revenue was $737.2 million and service revenue $755.5 million.
Gross margin improved to 45.8% from 45.1% as pricing, productivity and mix more than offset inflation. Income from operations rose to $285.8 million from $246.0 million, while net income attributable to shareholders increased to $200.1 million, or $2.04 diluted EPS, from $177.4 million, or $1.79.
Operating cash flow was $367.1 million and free cash flow $279.6 million after $87.5 million of capital spending. Total debt was $1,893.7 million, giving a debt‑to‑total capital ratio of 20.9%. The company repurchased 0.5 million shares for $100.0 million and began a new $1,000.0 million buyback program with $900.0 million remaining.
Remaining performance obligations were $1,541.4 million, with most expected to convert to revenue within a year. After largely completing a prior European restructuring, STERIS announced a new North Carolina chemistries consolidation, expecting $55–$70 million of pre‑tax restructuring charges through fiscal 2030.